2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement)

This Cost/Value Methodology Statement updates prior guidance regarding the incorporation of evidence from published CEAs into clinical guidelines. It provides guidance for identifying and synthesizing relevant high-quality evidence, developing economic value statements, and communicating level of certainty in such statements. It defines the US cost-effectiveness threshold as $120,000 per quality-adjusted life year gained, highlights special considerations related to cardiovascular drugs and devices, emphasizes health equity considerations when interpreting CEAs, and defines a reference case for future CEAs.

Authors

Publication Details

Journal
Journal of the American College of Cardiology
Published
2025-09-25
DOI
https://doi.org/10.1016/j.jacc.2025.05.009
Citations
3
Primary Topic
Clinical practice guidelines implementation
Type
article
Field-Weighted Citation Impact
5.64
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement)

Dhruv S Kazi, Inmaculada Hernandez, Karen E. Joynt Maddox, Kendra D. Sims et al.
3 citations
Journal of the American College of Cardiology
Clinical practice guidelines implementation
5.64
article

2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement)

Dhruv S Kazi, Inmaculada Hernandez, Karen E. Joynt Maddox, Kendra D. Sims, Merilyn S. Varghese, Derek S. Chew, Paul A. Heidenreich, Anirban Basu, Colette DeJong, Suzanne V. Arnold, Khadijah Breathett, Brandon Kyle Bellows, Ann Marie Návar, Liesl Zühlke, Apurvakumar Pandya, Nicolás Isaza, Abdul R. Abdullah, David J. Cohen, Susan Hennessy
article en
3 citations

Abstract

This Cost/Value Methodology Statement updates prior guidance regarding the incorporation of evidence from published CEAs into clinical guidelines. It provides guidance for identifying and synthesizing relevant high-quality evidence, developing economic value statements, and communicating level of certainty in such statements. It defines the US cost-effectiveness threshold as $120,000 per quality-adjusted life year gained, highlights special considerations related to cardiovascular drugs and devices, emphasizes health equity considerations when interpreting CEAs, and defines a reference case for future CEAs.

Journal of the American College of CardiologyVol. 87(9)
Openalex Percentile: Top 4%
Clinical practice guidelines implementation
5.64
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.